All Stories

  1. Upward Air Temperature Shifts and Acute Cardiovascular Events in Individuals with Atherosclerotic Cardiovascular Disease: A Time-Stratified Case-Crossover Study
  2. Plaque regression: Risk status or ApoB exposure?
  3. Multi-Omic Candidate Screening for Markers of Severe Clinical Courses of COVID-19
  4. De Novo Lipogenesis-Related Monounsaturated Fatty Acids in the Blood Are Associated with Cardiovascular Risk Factors in HFpEF Patients
  5. Weight-gain independent effect of mirtazapine on fasting plasma lipids in healthy men
  6. Trans-fatty acid blood levels of industrial but not natural origin are associated with cardiovascular risk factors in patients with HFpEF: a secondary analysis of the Aldo-DHF trial
  7. Trans-fatty acid blood levels of industrial but not natural origin are associated with cardiovascular risk factors in patients with HFpEF: a secondary analysis of the Aldo-DHF trial
  8. Obesity and cardiovascular disease: beyond body weight and energy balance
  9. Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF: A Secondary Analysis of the Aldo-DHF Trial
  10. Re-evaluating low-carbohydrate diets and mortality
  11. Weight-gain Independent Effect of Mirtazapine on Fasting Plasma Lipids in Healthy Men
  12. Low-Carb-Diäten – die unvoreingenommene und evidenzbasierte Betrachtung ist überfällig
  13. Erratum zu: Gesättigte Fettsäuren und kardiovaskuläres Risiko: Ist eine Revision der Ernährungsempfehlungen angezeigt?
  14. Gesättigte Fettsäuren und kardiovaskuläres Risiko
  15. Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial
  16. TCT Connect 2020 Trial Update: FORECAST, COMBINE OCT-FFR and DEFINE-PCI
  17. Waist-to-height ratio and metabolic phenotype compared to the Matsuda index for the prediction of insulin resistance
  18. Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression
  19. Correction to: Impact of a 2‑year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes
  20. Paradigmenwechsel in den Empfehlungen zur Ernährung bei Typ-2-Diabetes
  21. Personalisierte Behandlungskonzepte bei arterieller Hypertonie
  22. Kardiovaskuläre Manifestationen von COVID-19
  23. Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes
  24. Comparison of Waist-to-height Ratio, Hypertriglyceridemic Waist Phenotype, Triglycerides to HDL-C Ratio and Fasting Plasma Glucose With the Matsuda Index for the Prediction of Insulin Resistance/hyperinsulinemia
  25. The Effect of Exercise Intensity and Volume on Metabolic Phenotype in Patients with Metabolic Syndrome: A Randomized Controlled Trial
  26. Inter-individual differences in the response to an exercise training intervention in patients with metabolic syndrome
  27. Impact of A Two-Year Trial of Nutritional Ketosis on Indices of Cardiovascular Disease Risk in Patients With Type 2 Diabetes
  28. Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?
  29. Recommendations on sodium intake for cardiovascular health: conviction or evidence?
  30. Your athlete-patient has a high coronary artery calcification score—‘Heart of Stone’. What should you advise? Is exercise safe?
  31. How to prevent cardiovascular events from recurring
  32. High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation
  33. Vitamin D and athletic performance: perspectives and pitfalls
  34. The ‘heart’ of preventive cardiology: Lifestyle medicine for the treatment of cardiometabolic diseases
  35. Exercise recommendations in athletes with coronary artery calcification
  36. THERAPY OF ENDOCRINE DISEASE: Medical treatment of primary aldosteronism
  37. Lifestyle and Atherosclerosis
  38. Demenz und metabolisch-vaskuläre Risikofaktoren: Möglichkeiten der Prävention
  39. Are Atherogenic Lipoprotein Phenotype and Inflammation Indicative of Plaque Phenotype and Clinical Stability in Coronary Artery Disease?
  40. Poster Session 1
  41. Sind Low-Carb-Diäten lebensgefährlich?
  42. Effect of mirtazapine on glucose metabolism and resting energy expenditure: Observations in “super-healthy” men under highly standardized conditions
  43. Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men
  44. Mediterrane Ernährung hilfreich bei kardiovaskulärer Primärprävention
  45. Ernährungsempfehlungen beim metabolisch-vaskulären Syndrom
  46. A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial
  47. A Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, Independent of Recommended Macronutrient Replacement and Time Point of Consumption: a Prospective, Randomized, Controlled Trial
  48. Ernährungsempfehlungen beim metabolisch-vaskulären Syndrom
  49. WALNUT-ENRICHED DIET REDUCES LIPIDS IN HEALTHY CAUCASIAN SUBJECTS, INDEPENDENT OF RECOMMENDED MACRONUTRIENT REPLACEMENT
  50. So steuern Sie das Essverhalten Ihrer Patienten in die richtige Richtung
  51. Hydrothermally modified slow release corn starch: a potential new therapeutic option for treating hypoglycemia in autoimmune hypoglycemia (Hirata’s disease)